Research and Funding

Division of Neuroscience

Alzheimer's Disease Cooperative Study (ADCS)

The Division of Neuroscience launched the ADCS in 1991 to facilitate the testing of new drugs for the treatment of Alzheimer's disease, particularly drugs that might not otherwise be tested by industry. A consortium of academic medical centers and clinics collaborating on the development of Alzheimer’s treatments and diagnostic tools, the ADCS is coordinated by the University of California, San Diego under an NIA cooperative agreement. Made up of more than 70 research sites in the United States and Canada, the ADCS investigates promising interventions. In January 2013, the NIA renewed its support of the effort for the next 5 years.

ADCS clinical trials focus on interventions that may benefit people across the disease spectrum, from the detection of Alzheimer’s-related brain changes in people free of symptoms to the treatment of agitation in people with Alzheimer’s dementia. This includes the testing of:

  • Drugs that lack patent protection
  • Drugs under patent protection that are already marketed for other uses but which might prove useful for treating people with Alzheimer's disease
  • Novel compounds developed by individuals, academia, and pharmaceutical and small biotech companies

In addition to testing new therapies, the ADCS develops new evaluation instruments for clinical trials and innovative approaches to Alzheimer’s disease clinical trial design and analysis. The ADCS emphasizes collaboration and data sharing among its partner sites and with other research institutions.

A major component of the Division of Neuroscience’s Alzheimer’s Disease Translational Research Program, the ADCS is seeding drug development and increasing the number of promising therapies tested in people at the earliest stages of the disease, when treatment may be most effective.  To date, the ADCS has conducted 30 studies (23 drug trials and seven instrument development studies). It also provides infrastructure support to other NIA-funded clinical efforts, such as the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and Dominantly Inherited Alzheimer Network (DIAN).

For more information about the ADCS, including currently recruiting clinical trials, visit

Current ADCS Studies
Trials Status
A4 Trial Enrolling
NOBLE (T-817MA) Trial Enrollment completed
SNIFF Trial Enrollment temporarily suspended
Connect (AZD0530) Trial Enrolling
Exert (exercise in MCI) Trial Enrollment to be announced
Prazosin for Treating Agitation Trial Enrollment to be announced
CSF Pharmacodynamic Trial Enrollment to be announced
Resveratrol for Alzheimer’s Disease Enrollment completed
CERE-110 in Subjects with Mild to Moderate Alzheimer’s Disease Enrollment completed
Intravenous Immune Globulin (IVIg) for the Treatment of Mild to Moderate Alzheimer's Disease Enrollment completed
Home-Based Assessment Study Enrollment completed
Completed ADCS Studies
Trials Status/Results
RAGE Inhibitor (RI) Trial Completion date TBD
Docosahexanoic Acid (DHA) in Alzheimer’s Disease Completed in 2010
Antioxidants in Alzheimer’s Disease (Vitamins E and C, Alpha-lipoic Acid, Coenzyme Q) Completed in 2012
Huperzine A in Mild to Moderate Alzheimer’s Disease Completed in 2011
Valproate to Delay Agitation or Psychosis in Alzheimer's Disease Completed in 2011
Supplements  to Reduce Homocysteine and Slow Cognitive Decline  (Vitamins B6 and B12, Folic Acid) Completed in 2008
Simvastatin to Treat Alzheimer's Disease Completed in 2011
Quetiapine for Agitation or Psychosis in Dementia and Parkinsonism Completed in 2007
Improved Assessment Measures for Primary Alzheimer's Disease Prevention Trials Completion date TBD
Valproate for the Treatment of Agitation in Dementia Completed in 2005
Rofecoxib or Naproxen to Slow Cognitive Decline in Alzheimer’s Disease Completed in 2003
Normal Control Completion date TBD
Vitamin E or Donepezil to Treat Mild Cognitive Impairment Completed in 2005
Melatonin for Sleep Disturbance in Alzheimer’s Disease Completed in 2003
Estrogen Replacement Therapy to Treat Women with Mild to Moderate Alzheimer’s Disease Completed in 2000
Effect of Prednisone on Rate of Cognitive Decline in Alzheimer’s Completed in 2000
Haloperidol, Trazodone, and Behavior Management to Treat Agitation in Alzheimer’s Completed in 2000
Evaluation of Treatment Efficacy  Instruments Trial (English and Spanish) Completed in 1997
(Ref. 1; Ref. 2)
Selegiline and Vitamin E to Treat Alzheimer’s Disease Completed in 1997

See a list of all published ADCS study results (NIH PubMed) »